## 3 Results and Discussion
### Performance of the Docking Scores with Known Drugs
The interaction of venetoclax with the mutated BCL-2 G101V is expected to be lower than the activity toward BCL-2, based on the experimental information, among the six that  
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**Molecule** & **RbN** & **Molecule** & **RbR** & **Molecule** & **AASS** & **Molecule** & **Z-Score** & **Molecule** & **ECR** \\ \hline
600k & & & & & & & & & \\
865043 & \(-\)50.835 & 865043 & 18.429 & venetoclax & 0.156 & venetoclax & \(-\)2.015 & venetoclax & 0.513 \\
85734 & \(-\)48.062 & 603509 & 20.857 & 865043 & 0.229 & 865043 & \(-\)1.676 & 865043 & 0.246 \\
58208 & \(-\)48.048 & 3848519 & 34.857 & 603509 & 0.272 & 603509 & \(-\)1.398 & 603509 & 0.200 \\
63318 & \(-\)47.648 & 1662017 & 37.286 & gilteritinib & 0.280 & 85734 & \(-\)1.238 & 85734 & 0.174 \\
57874 & \(-\)46.830 & 77098 & 38.857 & 85734 & 0.291 & gilteritinib & \(-\)1.225 & 486475 & 0.174 \\
3648213 & \(-\)46.619 & 85734 & 39.000 & 58208 & 0.292 & 58208 & \(-\)1.205 & 58208 & 0.159 \\
81232 & \(-\)46.535 & venetoclax & 39.429 & 3848519 & 0.298 & 1662017 & \(-\)1.193 & 113155 & 0.149 \\
357573 & \(-\)46.287 & 58208 & 40.571 & 1662017 & 0.301 & 3848519 & \(-\)1.158 & 81232 & 0.146 \\
486475 & \(-\)45.935 & gilteritinib & 49.714 & 563042 & 0.316 & 486475 & \(-\)1.043 & 215587 & 0.143 \\
563042 & \(-\)45.685 & 52645531 & 51.571 & 486475 & 0.319 & 563042 & \(-\)0.995 & 1662017 & 0.138 \\
865043 & \(-\)50.835 & 865043 & 18.429 & venetoclax & 0.156 & venetoclax & \(-\)2.015 & venetoclax & 0.513 \\ \hline
600l & & & & & & & & & \\
24815245 & \(-\)56.941 & venetoclax & 6.857 & venetoclax & 0.027 & venetoclax & \(-\)2.550 & venetoclax & 0.505 \\ venetoclax & \(-\)56.263 & gilteritinib & 18.857 & gilteritinib & 0.190 & gilteritinib & \(-\)1.562 & 865043 & 0.256 \\ gilteritinib & \(-\)49.946 & 28782425 & 26.714 & 24815245 & 0.208 & 24815245 & \(-\)1.495 & gilteritinib & 0.241 \\
865043 & \(-\)48.613 & 24815245 & 30.167 & 865043 & 0.217 & 865043 & \(-\)1.414 & 604320 & 0.224 \\
357573 & \(-\)48.304 & 2259963 & 38.714 & 28782425 & 0.228 & 28782425 & \(-\)1.318 & 24815245 & 0.217 \\
3648213 & \(-\)46.160 & 52645531 & 40.000 & 50146 & 0.242 & 50146 & \(-\)1.142 & 50146 & 0.212 \\
28782425 & \(-\)45.071 & 865043 & 40.429 & 67970 & 0.253 & 67970 & \(-\)1.122 & 28782425 & 0.172 \\
1989522 & \(-\)44.955 & 101757 & 45.857 & 531919 & 0.273 & 52645531 & \(-\)1.012 & 84640 & 0.160 \\
3920809 & \(-\)43.894 & 1164165 & 47.857 & 52645531 & 0.275 & 531919 & \(-\)0.982 & 3648213 & 0.147 \\
2832023 & \(-\)43.338 & 67970 & 53.143 & 604320 & 0.284 & 1164165 & \(-\)0.948 & 215587 & 0.144 \\
24815245 & \(-\)56.941 & venetoclax & 6.857 & venetoclax & 0.027 & venetoclax & \(-\)2.550 & venetoclax & 0.505 \\ \hline
6 il3 & & & & & & & & \\
24815245 & \(-\)57.671 & 101757 & 25.143 & 24815245 & 0.224 & 24815245 & \(-\)1.458 & 24815245 & 0.230 \\
604320 & \(-\)51.421 & 52645531 & 30.857 & 101757 & 0.237 & 101757 & \(-\)1.374 & 111013 & 0.218 \\
59052 & \(-\)49.836 & 56495 & 36.857 & 56495 & 0.2  
found venetoclax as a promising BCL-2 inhibitor, Vina, Haddock(rigid), Haddock(flex) and Haddock(flex, water) ranked its inhibitory activity towards the mutated BCL-2 G101V lower than that of BCL-2, while Mlodock and Glide gave it a better inhibitory activity towards the mutated BCL-2 G101V than BCL-2. Using the consensus method to combine the results, the ECR ranked gilteritinib among the top 10 hits while it is excluded from the list of top 10 hits obtained from other consensus methods. Four of the consensus methods RbR, AASS, ZS, and ECR ranked venetoclax among the top 10 hits and even predicted it has the best inhibitor of the mutated BCL-2 G101V, by these four consensus methods. Furthermore, the known drug gilteritinib against FLAT3, is ranked among the top best inhibitors of the mutated BCL-2 G101V, by the docking scores (Mlodock, Rerank, and Haddock(flex)), and also by all of the five consensus methods.